Stockreport

Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs [Yahoo! Finance]

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF Research and Development Costs: $10.6 million for the quarter, up from $3 million in Q3 2023. Selling, General and Administrative Expenses: $35.2 million for the quar [Read more]